K Ulrich Ulli Bayer - Publications

UCHSC, Aurora, CO, United States 
Synaptic plasticity, Down syndrome, Schizophrenia, Addiction, Stroke, Global cerebral ischemia

36 high-probability publications. We are testing a new system for linking publications to authors. You can help! If you notice any inaccuracies, please sign in and mark papers as correct or incorrect matches. If you identify any major omissions or other inaccuracies in the publication list, please let us know.

Year Citation  Score
2021 Tullis JE, Buonarati OR, Coultrap SJ, Bourke AM, Tiemeier EL, Kennedy MJ, Herson PS, Bayer KU. GluN2B S1303 phosphorylation by CaMKII or DAPK1: no indication for involvement in ischemia or LTP. Iscience. 24: 103214. PMID 34704002 DOI: 10.1016/j.isci.2021.103214  0.336
2021 Brown CN, Cook SG, Allen HF, Crosby KC, Singh T, Coultrap SJ, Bayer KU. Characterization of six CaMKIIα variants found in patients with schizophrenia. Iscience. 24: 103184. PMID 34667946 DOI: 10.1016/j.isci.2021.103184  0.558
2021 Goodell DJ, Tullis JE, Bayer KU. Young DAPK1 knockout mice have altered pre-synaptic function. Journal of Neurophysiology. PMID 33881939 DOI: 10.1152/jn.00055.2021  0.335
2021 Cook SG, Buonarati OR, Coultrap SJ, Bayer KU. CaMKII holoenzyme mechanisms that govern the LTP versus LTD decision. Science Advances. 7. PMID 33853773 DOI: 10.1126/sciadv.abe2300  0.602
2020 Buonarati OR, Cook SG, Goodell DJ, Chalmers NE, Rumian NL, Tullis JE, Restrepo S, Coultrap SJ, Quillinan N, Herson PS, Bayer KU. CaMKII versus DAPK1 Binding to GluN2B in Ischemic Neuronal Cell Death after Resuscitation from Cardiac Arrest. Cell Reports. 30: 1-8.e4. PMID 31914378 DOI: 10.1016/J.Celrep.2019.11.076  0.55
2019 Chalmers NE, Yonchek J, Steklac KE, Ramsey M, Bayer KU, Herson PS, Quillinan N. Calcium/Calmodulin-Dependent Kinase (CaMKII) Inhibition Protects Against Purkinje Cell Damage Following CA/CPR in Mice. Molecular Neurobiology. PMID 31520314 DOI: 10.1007/S12035-019-01765-9  0.344
2019 Bayer KU, Schulman H. CaM Kinase: Still Inspiring at 40. Neuron. 103: 380-394. PMID 31394063 DOI: 10.1016/j.neuron.2019.05.033  0.417
2019 Cook SG, Goodell DJ, Restrepo S, Arnold DB, Bayer KU. Simultaneous Live Imaging of Multiple Endogenous Proteins Reveals a Mechanism for Alzheimer's-Related Plasticity Impairment. Cell Reports. 27: 658-665.e4. PMID 30995464 DOI: 10.1016/J.Celrep.2019.03.041  0.6
2018 Opazo P, Viana da Silva S, Carta M, Breillat C, Coultrap SJ, Grillo-Bosch D, Sainlos M, Coussen F, Bayer KU, Mulle C, Choquet D. CaMKII Metaplasticity Drives Aβ Oligomer-Mediated Synaptotoxicity. Cell Reports. 23: 3137-3145. PMID 29898386 DOI: 10.1016/J.Celrep.2018.05.036  0.44
2018 Cook SG, Bourke AM, O'Leary H, Zaegel V, Lasda E, Mize-Berge J, Quillinan N, Tucker CL, Coultrap SJ, Herson PS, Bayer KU. Analysis of the CaMKIIα and β splice-variant distribution among brain regions reveals isoform-specific differences in holoenzyme formation. Scientific Reports. 8: 5448. PMID 29615706 DOI: 10.1038/S41598-018-23779-4  0.499
2017 Woolfrey KM, O'Leary H, Goodell DJ, Robertson HR, Horne EA, Coultrap SJ, Dell'Acqua ML, Bayer KU. CaMKII regulates the de-palmitoylation and synaptic removal of AKAP79/150 to mediate structural LTD. The Journal of Biological Chemistry. PMID 29196604 DOI: 10.1074/Jbc.M117.813808  0.474
2017 Goodell DJ, Zaegel V, Coultrap SJ, Hell JW, Bayer KU. DAPK1 Mediates LTD by Making CaMKII/GluN2B Binding LTP Specific. Cell Reports. 19: 2231-2243. PMID 28614711 DOI: 10.1016/j.celrep.2017.05.068  0.482
2016 Barcomb K, Hell JW, Benke TA, Bayer KU. The CaMKII/GluN2B interaction maintains synaptic strength. The Journal of Biological Chemistry. PMID 27246855 DOI: 10.1074/Jbc.M116.734822  0.423
2014 Tao-Cheng JH, Yang Y, Bayer KU, Reese TS, Dosemeci A. NMDA-induced accumulation of Shank at the postsynaptic density is mediated by CaMKII. Biochemical and Biophysical Research Communications. 450: 808-11. PMID 24952157 DOI: 10.1016/j.bbrc.2014.06.049  0.301
2014 Barcomb K, Buard I, Coultrap SJ, Kulbe JR, O'Leary H, Benke TA, Bayer KU. Autonomous CaMKII requires further stimulation by Ca2+/calmodulin for enhancing synaptic strength. Faseb Journal : Official Publication of the Federation of American Societies For Experimental Biology. 28: 3810-9. PMID 24843070 DOI: 10.1096/Fj.14-250407  0.445
2014 Goodell DJ, Eliseeva TA, Coultrap SJ, Bayer KU. CaMKII binding to GluN2B is differentially affected by macromolecular crowding reagents. Plos One. 9: e96522. PMID 24796865 DOI: 10.1371/journal.pone.0096522  0.354
2014 Turecek J, Yuen GS, Han VZ, Zeng XH, Bayer KU, Welsh JP. NMDA receptor activation strengthens weak electrical coupling in mammalian brain. Neuron. 81: 1375-88. PMID 24656255 DOI: 10.1016/J.Neuron.2014.01.024  0.363
2014 Coultrap SJ, Freund RK, O'Leary H, Sanderson JL, Roche KW, Dell'Acqua ML, Bayer KU. Autonomous CaMKII mediates both LTP and LTD using a mechanism for differential substrate site selection. Cell Reports. 6: 431-7. PMID 24485660 DOI: 10.1016/j.celrep.2014.01.005  0.443
2013 Yang Y, Tao-Cheng JH, Bayer KU, Reese TS, Dosemeci A. Camkii-mediated phosphorylation regulates distributions of Syngap-α1 and -α2 at the postsynaptic density. Plos One. 8: e71795. PMID 23967245 DOI: 10.1371/journal.pone.0071795  0.349
2011 O'Leary H, Liu WH, Rorabaugh JM, Coultrap SJ, Bayer KU. Nucleotides and phosphorylation bi-directionally modulate Ca2+/calmodulin-dependent protein kinase II (CaMKII) binding to the N-methyl-D-aspartate (NMDA) receptor subunit GluN2B. The Journal of Biological Chemistry. 286: 31272-81. PMID 21768120 DOI: 10.1074/Jbc.M111.233668  0.438
2011 Sanhueza M, Fernandez-Villalobos G, Stein IS, Kasumova G, Zhang P, Bayer KU, Otmakhov N, Hell JW, Lisman J. Role of the CaMKII/NMDA receptor complex in the maintenance of synaptic strength. The Journal of Neuroscience : the Official Journal of the Society For Neuroscience. 31: 9170-8. PMID 21697368 DOI: 10.1523/JNEUROSCI.1250-11.2011  0.376
2011 Coultrap SJ, Vest RS, Ashpole NM, Hudmon A, Bayer KU. CaMKII in cerebral ischemia. Acta Pharmacologica Sinica. 32: 861-72. PMID 21685929 DOI: 10.1038/Aps.2011.68  0.38
2010 Marsden KC, Shemesh A, Bayer KU, Carroll RC. Selective translocation of Ca2+/calmodulin protein kinase IIalpha (CaMKIIalpha) to inhibitory synapses. Proceedings of the National Academy of Sciences of the United States of America. 107: 20559-64. PMID 21059908 DOI: 10.1073/Pnas.1010346107  0.441
2010 Buard I, Coultrap SJ, Freund RK, Lee YS, Dell'Acqua ML, Silva AJ, Bayer KU. CaMKII "autonomy" is required for initiating but not for maintaining neuronal long-term information storage. The Journal of Neuroscience : the Official Journal of the Society For Neuroscience. 30: 8214-20. PMID 20554872 DOI: 10.1523/Jneurosci.1469-10.2010  0.342
2010 Vest RS, O'Leary H, Coultrap SJ, Kindy MS, Bayer KU. Effective post-insult neuroprotection by a novel Ca(2+)/ calmodulin-dependent protein kinase II (CaMKII) inhibitor. The Journal of Biological Chemistry. 285: 20675-82. PMID 20424167 DOI: 10.1074/Jbc.M109.088617  0.33
2010 Coultrap SJ, Buard I, Kulbe JR, Dell'Acqua ML, Bayer KU. CaMKII autonomy is substrate-dependent and further stimulated by Ca2+/calmodulin. The Journal of Biological Chemistry. 285: 17930-7. PMID 20353941 DOI: 10.1074/Jbc.M109.069351  0.371
2009 Vest RS, O'Leary H, Bayer KU. Differential regulation by ATP versus ADP further links CaMKII aggregation to ischemic conditions. Febs Letters. 583: 3577-81. PMID 19840793 DOI: 10.1016/J.Febslet.2009.10.028  0.327
2007 Vest RS, Davies KD, O'Leary H, Port JD, Bayer KU. Dual mechanism of a natural CaMKII inhibitor. Molecular Biology of the Cell. 18: 5024-33. PMID 17942605 DOI: 10.1091/Mbc.E07-02-0185  0.369
2006 Bayer KU, LeBel E, McDonald GL, O'Leary H, Schulman H, De Koninck P. Transition from reversible to persistent binding of CaMKII to postsynaptic sites and NR2B. The Journal of Neuroscience : the Official Journal of the Society For Neuroscience. 26: 1164-74. PMID 16436603 DOI: 10.1523/JNEUROSCI.3116-05.2006  0.688
2003 Fink CC, Bayer KU, Myers JW, Ferrell JE, Schulman H, Meyer T. Selective regulation of neurite extension and synapse formation by the beta but not the alpha isoform of CaMKII. Neuron. 39: 283-97. PMID 12873385 DOI: 10.1016/S0896-6273(03)00428-8  0.54
2002 Leonard AS, Bayer KU, Merrill MA, Lim IA, Shea MA, Schulman H, Hell JW. Regulation of calcium/calmodulin-dependent protein kinase II docking to N-methyl-D-aspartate receptors by calcium/calmodulin and alpha-actinin. The Journal of Biological Chemistry. 277: 48441-8. PMID 12379661 DOI: 10.1074/Jbc.M205164200  0.574
2002 Bayer KU, De Koninck P, Schulman H. Alternative splicing modulates the frequency-dependent response of CaMKII to Ca(2+) oscillations. The Embo Journal. 21: 3590-7. PMID 12110572 DOI: 10.1093/emboj/cdf360  0.639
2001 Bayer KU, Schulman H. Regulation of signal transduction by protein targeting: the case for CaMKII. Biochemical and Biophysical Research Communications. 289: 917-23. PMID 11741277 DOI: 10.1006/bbrc.2001.6063  0.505
2001 Bayer KU, De Koninck P, Leonard AS, Hell JW, Schulman H. Interaction with the NMDA receptor locks CaMKII in an active conformation. Nature. 411: 801-5. PMID 11459059 DOI: 10.1038/35081080  0.679
1999 Bayer KU, Löhler J, Schulman H, Harbers K. Developmental expression of the CaM kinase II isoforms: ubiquitous gamma- and delta-CaM kinase II are the early isoforms and most abundant in the developing nervous system. Brain Research. Molecular Brain Research. 70: 147-54. PMID 10381553 DOI: 10.1016/S0169-328X(99)00131-X  0.417
1998 Bayer KU, Harbers K, Schulman H. alphaKAP is an anchoring protein for a novel CaM kinase II isoform in skeletal muscle. The Embo Journal. 17: 5598-605. PMID 9755160 DOI: 10.1093/emboj/17.19.5598  0.417
Show low-probability matches.